Pol Arch Intern Med. 2017 Dec 22;127(12):823-831. doi: 10.20452/pamw.4117. Epub 2017 Sep 30.
INTRODUCTION Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative to vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). OBJECTIVES The aim of the study was to assess the incidence of left atrial appendage (LAA) thrombus and dense spontaneous echo contrast (SEC), as well as to compare the clinical characteristics of patients with AF treated with different anticoagulant regimens. PATIENTS AND METHODS We studied 1033 consecutive patients with AF, who underwent transesophageal echocardiography (TEE) before AF ablation or cardioversion. We excluded 174 patients without any prior oral anticoagulation or who underwent bridging with heparin before TEE. RESULTS In the study group of 859 patients (median age, 61 years; men, 66%), 437 patients (50.9%) received VKAs; 191 (22.2%), dabigatran; 230 (26.8%), rivaroxaban; and 1 patient (0.1%), apixaban. There were no differences in baseline characteristics or the incidence of LAA thrombus (VKAs, 6.9%; NOACs, 5.5%; P = 0.40) and dense SEC (VKAs, 5.3%; NOACs, 3.3%; P = 0.18) between patients on VKAs and those on NOACs. Compared with patients treated with dabigatran, those on rivaroxaban more often had paroxysmal AF, higher ejection fraction, LAA emptying velocity, and platelet count, as well as lower left ventricular end‑diastolic dimension and hematocrit. The frequency of LAA thrombus in patients receiving dabigatran and those receiving rivaroxaban was comparable (6.8% vs 4.4%; P = 0.29), while dense SEC occurred more often in patients treated with dabigatran (5.2% vs 1.7%; P = 0.06). In a logistic regression analysis, none of the oral anticoagulation regimens predicted LAA thrombus in TEE, whereas maximal LAA emptying velocity was the only parameter independently associated with the presence of thrombus. CONCLUSIONS In the studied group of patients with AF, the choice of anticoagulation did not depend on thromboembolic or bleeding risk.
简介 非维生素 K 拮抗剂口服抗凝剂(NOACs)是预防心房颤动(AF)中风的维生素 K 拮抗剂(VKAs)的替代方法。
目的 本研究的目的是评估左心耳(LAA)血栓和密集自发性回声对比(SEC)的发生率,并比较接受不同抗凝方案治疗的 AF 患者的临床特征。
患者和方法 我们研究了 1033 例连续接受 AF 消融或电复律的经食管超声心动图(TEE)的 AF 患者。我们排除了 174 例无任何先前口服抗凝治疗或在 TEE 前接受肝素桥接的患者。
结果 在研究组的 859 例患者(中位年龄 61 岁;男性 66%)中,437 例(50.9%)接受 VKAs;191 例(22.2%)接受达比加群;230 例(26.8%)接受利伐沙班;1 例(0.1%)接受阿哌沙班。VKAs 组(6.9%)和 NOACs 组(5.5%)的 LAA 血栓(P=0.40)和密集 SEC(P=0.18)发生率无差异。与接受 VKAs 的患者相比,接受利伐沙班的患者更常患有阵发性 AF、射血分数更高、LAA 排空速度更快、血小板计数更高,而左心室舒张末期内径和红细胞压积更低。接受达比加群和利伐沙班治疗的患者的 LAA 血栓发生率相当(6.8%vs4.4%;P=0.29),而接受达比加群治疗的患者 SEC 更常见(5.2%vs1.7%;P=0.06)。在逻辑回归分析中,没有一种口服抗凝方案可以预测 TEE 中的 LAA 血栓,而最大 LAA 排空速度是唯一与血栓存在相关的参数。
结论 在研究的 AF 患者组中,抗凝选择不取决于血栓栓塞或出血风险。